Celutriator is a fully automated rare cell enrichment system specifically engineered for clinical samples. Its label-free microfluidic technology requires no antibodies nor centrifugation, maintaining full cell viability and biological function.
One of the key innovative features is the integration of a reusable microfluidic chip as a permanent internal component of the system. This design reduces long-term operational expenditure and mitigates the inter-batch performance variability associated with disposable chips. The system's whole-blood processing capability enables one-click sample-to-result operation with no dedicated technical personnel needed, making it ideal for rapid clinical cell sorting applications.
The core sorting module μFCPU (Microfluidic Cell Processing Unit) integrated into Celutriator leverages the latest breakthrough from the original research team that pioneered a serials of spiral inertial microfluidic technologies. With an unprecedented sorting throughput of 10⁸ cells per second (cps), it enables Celutriator to process 7.5 mL of whole blood in just 10 minutes.
The μFCPU is fabricated using our proprietary LMAC process. Constructed from highly stable materials, the module contains no irreversible modifications, allowing for long-term repeated use.
1. Using the Celutriator to CTCs from multiple breast cancer patients, perform single-cell transcriptomic analysis and in situ expression profiling, to identify a unique tumor cell subpopulation and uncover potential therapeutic targets for breast cancer treatment.
2. Clinical validation demonstrated that fetal circulating trophoblasts (CTBs) could be successfully obtained from the peripheral blood of 86.67% of 30 pregnancy cases using the Celutriator. Single-base variants in the HBB gene could be accurately detected by sequencing these rare CTBs.
3. By leveraging the Celutriator isolation and enrichment and enrich CTCs from CDX mouse models, potent inducers of CTC senescence could be screened and identified to elucidate the mechanisms underlying CTC senescence promotion, apoptosis induction, and melanoma metastasis inhibition, and explore potential novel therapeutic strategies for metastatic melanoma.
